Not only does a top cancer research hospital offer complicated procedures, but it also has the ability to connect scientific discovery with patient care. This kind of institution works like a living ecosystem, turning new discoveries in the lab into new ways to treat and research cancer that can save lives. It must follow two goals: to offer the best treatments available today and to work on finding the best cures for tomorrow.
This strict standard is followed by GoBroad Healthcare Group. The Group is a pioneer of the research-oriented hospital model in China. They are working on building a closed-loop system called the Academic Research Organization (ARO). This organizational strategy combines clinical discovery, basic research, industrial transformation, and clinical application. This makes sure that patients quickly and directly benefit from the latest developments in cancer research and treatment.
Leading the way in cellular and transplant therapies
A world-class cancer research hospital’s main specialty should be its ability to use advanced treatment methods, especially those that are at the cutting edge of immunotherapy and stem cell biology. For GoBroad Healthcare Group, this knowledge is mostly about cellular therapy and transplants.
The Group is now a national leader in adoptive cell therapy, especially Chimeric Antigen Receptor T cell (CAR-T) immunotherapy. This personalized treatment, which involves changing a patient’s T cells so they attack cancer, is a direct result of a lot of work on cancer research and treatment.
GoBroad Healthcare Group has a lot of experience:
- Volume: Successfully using CAR-T cell therapy to treat almost 5,000 patients.
- Impact: The Group’s experts have helped the world understand cellular therapy a lot by writing more than 70 academic papers and giving more than 100 talks at major international conferences like ASH and ASCO.
The Group can handle the complicated parts of cellular therapy, like choosing patients, making treatments just for them, and dealing with possible side effects. This gives patients access to treatments that are hard to find elsewhere.
Hematopoietic Stem Cell Transplantation (HSCT)
GoBroad Healthcare Group is also very good at Hematopoietic Stem Cell Transplantation (HSCT), which is also called Bone Marrow Transplantation (BMT). HSCT is still the best way to get long-term remission for many high-risk hematologic cancers. The Group has done a lot of good work in this area, having done more than 1,200 transplants and always improving techniques like the TCRαβ-T Cell Depleted Allogeneic HSCT to lower the risk of complications like GVHD.
Integrated diagnostics are the basis for a modern cancer research hospital.Being able to offer advanced treatments is useless if you can’t accurately and precisely identify diseases. So, the second most important thing about a top school is that it is dedicated to integrated diagnostics.
A modern cancer research hospital uses diagnostic tools not only to name a disease, but also to find its genetic and molecular weaknesses. The Precision Diagnostics Center at GoBroad Healthcare Group uses a number of advanced technologies together:
Next-Generation Sequencing (NGS) gives a full genetic profile of solid tumors and blood cancers, finding specific mutations that advanced drugs can target.
Flow Cytometry and FISH: These are used to look at blood cell populations and chromosomal abnormalities in great detail. They are very important for keeping an eye on how a disease is getting worse and for finding minimal residual disease (MRD) after treatment.
To make sure that complicated treatments like CAR-T work as well as possible, we need this level of detailed diagnostic information. It will also help us plan the next steps in cancer research and treatment.
Speeding up new ideas through clinical research
What really sets a top cancer research hospital apart is its commitment to moving the field forward through clinical trials. Research is not something that can be added on; it is an integral part of how the hospital works.
GoBroad Healthcare Group helps with this mission by keeping up a lot of research facilities, like Phase I clinical trial wards and a Central Laboratory. The Group makes it easier for hundreds of cutting-edge pharmaceutical companies to work together by:
Early-Phase Trials: Giving patients with severe or hard-to-treat diseases access to new investigational treatments years before they are widely available.
Translational Medicine: Running an ecosystem where “clinical discovery” informs “basic research” to make sure that research questions are directly related to the needs of patients right now. This includes knowledge in both hematologic malignancies and solid tumor oncology, where the Group’s teams have made important contributions to journals like The Lancet and Nature Medicine on gastric cancer and T-ALL.
The Multidisciplinary Care (MDC) model makes it official that this cancer research and treatment pipeline works together smoothly. This framework brings together oncologists, pathologists, researchers, and specialists to work together to find the best, most personalized path for each patient. This way, every patient can benefit from the combined knowledge and research base of the entire GoBroad Healthcare Group network.
GoBroad Healthcare Group is still working toward its goal of improving medical innovation and giving patients with complicated cancers life-changing results by focusing on cellular therapy, integrated diagnostics, and a strong translational research system.
